We are live on ! Find out more
DCM

Defilade Capital Management Portfolio holdings

AUM $747M
This Fund
S&P 500
This Quarter Est. Return
+5.84%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$747M
AUM Growth
+$34.8M
Cap. Flow
+$1.91M
Cap. Flow %
0.26%
Top 10 Hldgs %
46.51%
Holding
50
New
19
Increased
9
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
VEEV icon
Veeva Systems
VEEV
+$39M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$37.4M
3
PODD icon
Insulet
PODD
+$29.5M
4
BAX icon
Baxter International
BAX
+$27.2M
5
ABT icon
Abbott
ABT
+$26.1M

Top Sells

Rank Stock Value
1
HSIC icon
Henry Schein
HSIC
+$46M
2
BDX icon
Becton Dickinson
BDX
+$43.9M
3
RVMD icon
Revolution Medicines
RVMD
+$34.1M
4
DXCM icon
DexCom
DXCM
+$33.8M
5
ISRG icon
Intuitive Surgical
ISRG
+$31.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
26
Oric Pharmaceuticals
ORIC
$1.44B
$11.3M 1.52%
1,047,690
+204,762
+24% +$1.86M
LRMR icon
27
Larimar Therapeutics
LRMR
$433M
$11.2M 1.5%
+3,670,135
New +$14.6M
GMED icon
28
Globus Medical
GMED
$11.2B
$11M 1.48%
139,637
-214,713
-61% -$18.2M
ENOV icon
29
Enovis
ENOV
$1.46B
$11M 1.47%
+531,945
New +$12.5M
EVMN
30
Evommune Inc
EVMN
$512M
$10.5M 1.41%
793,145
+114,556
+17% +$2.66M
TFX icon
31
Teleflex
TFX
$5.88B
$10.2M 1.36%
+80,118
New +$10.3M
DNLI icon
32
Denali Therapeutics
DNLI
$3.93B
$10.1M 1.35%
391,866
-968,103
-71% -$19.9M
GKOS icon
33
Glaukos
GKOS
$10.7B
$9.3M 1.24%
+66,519
New +$8.42M
STAA icon
34
STAAR Surgical
STAA
$1.15B
$9.24M 1.24%
+322,126
New +$8.96M
PACS icon
35
PACS Group
PACS
$7.03B
$9.2M 1.23%
215,675
-388,505
-64% -$14M
CRNX icon
36
Crinetics Pharmaceuticals
CRNX
$9B
$8.96M 1.2%
+239,440
New +$8.9M
LIVN icon
37
LivaNova
LIVN
$4.41B
$8.83M 1.18%
+107,373
New +$7.59M
BDTX icon
38
Black Diamond Therapeutics
BDTX
$130M
$3.1M 0.41%
+1,674,999
New +$4.1M
MREO
39
Mereo BioPharma
MREO
$44.4M
$2.4M 0.32%
7,558,756
– –
ALGN icon
40
Align Technology
ALGN
$11.3B
– –
-67,332
Closed -$11.5M
BDX icon
41
Becton Dickinson
BDX
$51.8B
– –
-279,210
Closed -$43.9M
BHVN icon
42
Biohaven
BHVN
$2.56B
– –
-315,944
Closed -$2.67M
BIIB icon
43
Biogen
BIIB
$32.7B
– –
-96,289
Closed -$17.7M
DXCM icon
44
DexCom
DXCM
$33.6B
– –
-538,762
Closed -$33.8M
HSIC icon
45
Henry Schein
HSIC
$10.1B
– –
-624,037
Closed -$46M
ISRG icon
46
Intuitive Surgical
ISRG
$131B
– –
-67,681
Closed -$31.2M
ITGR icon
47
Integer Holdings
ITGR
$4.26B
– –
-213,027
Closed -$18.7M
NBIX icon
48
Neurocrine Biosciences
NBIX
$15.9B
– –
-209,932
Closed -$27.7M
NUVL
49
DELISTED
Nuvalent
NUVL
– –
-129,950
Closed -$13.3M
TNDM icon
50
Tandem Diabetes Care
TNDM
$1.49B
– –
-761,905
Closed -$14.6M
1
2

Similar funds

BG
BDF Gestion Paris, France $747M AUM 47.35% 1-Year Est. Return
PCM
Permanent Capital Management Chicago, Illinois $747M AUM 17.94% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $748M AUM 27.21% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $745M AUM 23.99% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $745M AUM 27.52% 1-Year Est. Return
VCM
Virtue Capital Management Brentwood, Tennessee $749M AUM 40.13% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $745M AUM 25.89% 1-Year Est. Return
CCME
CIBC Capital Markets (Europe) Luxembourg $745M AUM

Defilade Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Defilade Capital Management held 50 positions worth $747M, up 4.9% from $712M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Defilade Capital Management's Q2 2026 filing shows 19 new, 9 increased, 10 reduced and 11 closed positions. Its largest new stake was Veeva Systems: 236,709 shares worth $42M. The largest sale was Henry Schein, an estimated $46M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Defilade Capital Management's largest Q2 2026 buy was Veeva Systems: 236,709 shares worth $42M.
  • Defilade Capital Management added most to Eli Lilly in Q2 2026, an estimated $18.8M increase.
  • Defilade Capital Management's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $34.1M.
  • Defilade Capital Management fully exited Henry Schein in Q2 2026, selling an estimated $46M.
  • Defilade Capital Management's ten largest holdings make up 47% of its $747M portfolio in Q2 2026.
  • Defilade Capital Management opened 19 new positions and closed 11 in Q2 2026.
  • Defilade Capital Management's portfolio value rose 4.9% quarter-over-quarter to $747M.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.